Ionis adds former Alexion CEO Ludwig Hantson to board

Ionis Pharmaceuticals

Ionis Pharmaceuticals

IONS

0.00
  • Ionis Pharmaceuticals named former Alexion CEO Ludwig Hantson to its board, effective immediately.
  • Hantson led Alexion from 2017 to 2021 through its sale to AstraZeneca.
  • He previously ran Baxter Bioscience, led the Baxalta spin-off as CEO, held senior roles at Novartis, spent 13 years at Johnson & Johnson.
  • Ionis also added Peter Reikes to the board.
  • Directors Joseph Wender, Lynne Parshall retired.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-024407), on June 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.